Retatrutide, a new dual agonist of the GLP-1 target and glucose-dependent released polypeptide (GIP) binding site , is exhibiting promising outcomes in initial clinical studies. Current research indicates that retatrutide may offer substantial improvements for patients with obesity, particularly regarding body mass loss and glucose management . Fur